Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

The US Food and Drug Administration (FDA) has approved Novavax's Covid-19 vaccine, Nuvaxovid, but only for limited use in ...

My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America. And I'm very pleased to be joined by many members of the senior leadership team at Novavax, including John ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...

Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about upcoming trade deals and economic partnerships with other countries.

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Novavax ( NASDAQ:NVAX ) First Quarter 2025 ...